Tessa announced, EMA has granted PRiority MEdicines designation to the company's lead autologous CD30 CAR-T therapy for the treatment of relapsed or refractory ... Jan 19
Annamycin is capable of reaching 6 to 34-fold higher levels of accumulation in the lungs than that of doxorubicin, the primary first-line chemotherapy ... Dec 29
The pharma company continues to plan for a mid-2021 launch of JZP-458 following completion of the BLA submission and US FDA review and ... Dec 23
Subcutaneous administration is preferred by patients, physicians and healthcare providers, and is associated with a reduction in healthcare costs ... Dec 23
The company plans to begin a Phase 1/2 clinical trial of KB-0742 in patients with advanced solid tumours in the first quarter of ... Dec 08
This collaboration, which combines KaliVir's expertise in the development of oncolytic viruses with Astellas' capabilities in advanced drug development... Dec 07
I-Mab's global collaboration with AbbVie will facilitate global development of lemzoparlimab... Dec 05
Senhwa announces multiple IND application submissions to US FDA and Health Canada evaluating its investigational drug, CX-5461, for the treatment of patients with solid ... Nov 26
QIAGEN collaborates with BioNTech on companion diagnostics development for HPV-associated squamous cell carcinoma of the head and neck ... Nov 19
PharmaTher Inc collaborates with Revive Therapeutics for psilocybin and panaceAI psychedelic discovery AI platform ... Nov 19
Gritstone Oncology advances into phase 2 expansion cohorts for its personalized neoantigen immunotherapy GRANITE and its off-the-shelf neoantigen immunotherapy SLATE ... Nov 03
Sumitomo Dainippon Pharma Oncology announces first patient dosed with TP-1454 in patients with advanced solid tumours ... Oct 10
-Advertisements-
.jpeg)
Wednesday, August 26, 2026
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)